Contribution of polymorphisms in the apolipoprotein AI-CII-AIV cluster to hyperlipidaemia in patients with gout

Annals of the Rheumatic Diseases

Volumn 64, Issue 1, 2005, Pages 85-88

  Cardona, F ^a   Tinahones, F J ^a   Collantes, E ^b   Escudero, A ^b   Garcia Fuentes E ^a   Soriguer, F J ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALLELE; APOLIPOPROTEIN A1 GENE; APOLIPOPROTEIN AI CIII AIV GENE; APOLIPOPROTEIN CIII GENE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA DETERMINATION; GENE; GENE AMPLIFICATION; GENE CLUSTER; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; HYPERLIPIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MSPL GENE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SSTL GENE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID URINE LEVEL; XMNL GENE;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; APOLIPOPROTEINS; APOLIPOPROTEINS A; APOLIPOPROTEINS C; GENETIC PREDISPOSITION TO DISEASE; GOUT; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC;

EID: 11444264663     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.019695     Document Type: Article

References (41)

1. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and coronary heart disease. Ann Intern Med 1951;34:1421-31.
2. Iribarren C, Sharp DS, Curb JD, Yano K. High uric acid: a metabolic marker of coronary heart disease among alcohol abstainers? J Clin Epidemiol 1996;49:673-8.
3. Rathmann W, Hauner H, Dannehl K, Gries FA. Association of elevated uric acid with coronary heart disease in diabetes mellitus. Diabete Metab 1993;19:159-66.
4. Vuorinen-Markkola H, Yki-Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994;78:25-9.
5. Facchini F, Chen Y-D I, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008-11.
6. Galvan AQ, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995;268:E1-5.
7. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-81.
8. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid a facet of hyperinsulinemia. Diabetologia 1987;30:713-18.
9. Selby JV, Friedman GD, Quesenberry CP. Precursors of essential hypertension: Pulmonary function, heart rate, uric acid, serum cholesterol, and other chemistries. Am J Epidemiol 1990;131:1017-27.
10. Zavaroni I, Mazza S, Fantuzzi M, Dall'Aglio E, Bonora E, Delsignore R, et al. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricemia. J Intern Med 1993;234:25-30.
11. Wyngaarden JB, Kelley WN. Gout. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1983:1043-14.
12. Folsom AR, Burke GL, Ballew C, Jacobs DR, Haskell WL, Donahue RP, et al. Relation of body fatness and its distribution to cardiovascular risk factors in young blacks and whites. The role of insulin. Am J Epidemiol 1989;130:911-24.
13. Tinohones FJ, Vazquez F, C-Soriguer FJ, Collantes E. Lipoproteins in patients with isolated hyperuricemia. Adv Exp Med Biol 1998;431:61-7.
14. Tinahones FJ, Collantes E, C-Soriguer FJ, Gonzalez-Ruiz A, Pineda M, Anon J, et al. Increased VLDL levels and diminished renal excretion of uric acid in hyperuncaemic-hypertriglyceridaemic patients. Br J Rheumatol 1995;34:920-4.
15. Groenendijk M, Cantor RM, De Bruin TWA, Dallinga-Thie GM. New genetic variants in the apoA-I and apoC-III genes and familial combined hyperlipidemia. J Lipid Res 2001;42:188-94.
16. Waterworth DM, Ribalta J, Nicaud V, Dallongeville J, Humphries SE, Talmud P. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 1999;99:1872-7.
17. Ferns GM, Ritchie C, Stocks J, Galton DJ. Genetic polymorphisms of apolipoprotein C-III and insulin in survivors of myocardial infarction. Lancet 1985;ii:300-3.
18. Ordovás JM, Civeira F, Genest JJ, Craig S, Robbins AH, Meade T, et al. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III and A-IV gene locus: relationships with lipids, apolipoproteins and premature coronary artery disease. Atherosclerosis 1991;87:75-86.
19. López Miranda J, Jansen S, Ordovás JM, Salas J, Marín C, Castro P, et al. Influence of the Sst1 polymorphic site at the apolipoprotein C-III gene on plasma LDL cholesterol response to monounsaturated dietary fat. Am J Clin Nutr 1997;66:97-103.
20. Danek GM, Valenti M, Baralle FE, Romano M. The A/G polymorphism in the -78 position of the apolipoprotein A-I promoter does not have a direct effect on transcriptional efficiency. Biochem Biophys Acta 1998;1398:67-74.
21. Xu CF, Angelica F, Del Ben M, Humphries SE. Role of genetic variation at the apo AI-CIII-AIV gene cluster in determining plasma apo A-I levels in boys and girls. Genet Epidemiol 1993;10:113-22.
22. Barre DE, Guerra R, Verstraete R, Wang Z, Grundy SM, Cohen JC. Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter; effect on plasma HDL-cholesterol levels. J Lipid Res 1994;35:1.292-6.
23. Civeira F, Pocovi M, Cenarro A, Garcés C, Ordovás JM. Adenine for guanine substitution. 78 base pairs to the apolipoprotein (apo) A-I gene: relation with high density lipoprotein cholesterol and apo A-I concentrations. Clin Genet 1993;44:307-12.
24. Soriguer-Escofet F, Estevo I, Rojo-Martinez G, Ruiz de Adana S, Catala M, Merelo MJ, et al. Diabetes Group of the Andalusian Society of Endocrinology and Nutrition. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Res Clin Pract 2002;56:213-20.
25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
26. Queipo-Ortuno MI, Garcia-Ordonez MA, Colmenero JD, Morata P. Hydrogen peroxide improves the efficiency of a peripheral blood PCR assay for diagnosis of human brucellosis. Biotechniques 1999;27:248-50, 252.
27. Shoulders CC, Narcisi TM, Jarmuz A, Brett DJ, Bayliss JD, Scott J. Characterization of genetic markers in the 5′ flanking region of the apo A1 gene. Hum Gene 1993;91:197-8.
28. Jeenoh M, Kessling A, Miller N, Humphries S. G to A substitution in the promoter region of the apolipoprotein A1 gene is associated with elevated serum apolipoprotein A1 and high density lipoprotein cholesterol concentrations. Mol Biol Med 1990;7:233-41.
29. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3_UTR polymorphisms. Proc Natl Acad Sci USA 1993;90:4562-6.
30. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998;8:250-61.
31. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002;47:610-13.
32. Tinahones FJ, Collantes E, C-Soriguer FJ, Gonzalez-Ruiz A, Pineda M, Anon J, et al. Increased VLDL levels and diminished renal excretion of uric acid in hyperuricaemic-hypertriglyceridaemic patients. Br J Rheumatol 1995;34:920-4.
33. Tinahones JF, Perez-Lindon G, C-Soriguer FJ, Pareja A, Sanchez-Guijo P, Collantes E. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J Clin Endocrinol Metab 1997;82:1188-91.
34. Cardona F, Tinahones FJ, Collantes E, Escudero A, Garcia-Fuentes E, Soriguer FJ. The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. Rheumatology (Oxford) 2003;42:468-72.
35. Dallinga-Thie GM, Bu XD, van Linde-Sibenius Trip M, Rotter JI, Lusis AJ, de Bruin TW. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996;37:136-47.
36. Meng QH, Pajukanta P, Valsta L, Aro A, Pietinen P, Tikkanen MJ. Influence of apolipoprotein A-I promoter polymorphism on lipid levels and responses to dietary change in Finnish adults. J Intern Med 1997;241:373-8.
37. Wang XL, Badenhop R, Humphrey KE, Wilcken DE. C to T and/or G to A transitions are responsible for loss of a Msp1 restriction site at the 5′-end of the human apolipoprotein A1 gene. Hum Genet 1995;95:473-4.
38. Wang XL, Liu SX, McCredie RM, Wilcken DE. Polymorphisms at the 5′-end of the apolipoprotein A1 gene and severity of coronary artery disease. J Clin Invest 1996;98:372-7.
39. Wang XL, Badenhop R, Humphrey KE, Wilcken DE. New Msp1 polymorphism at +83 bp of the human apolipoprotein A1 gene: association with increased circulating high density lipoprotein cholesterol levels. Genet Epidemiol 1996;13:1-10.
40. Kessling AM, Horsthemke B, Humphries SE. A study of DNA polymorphisms around the human apolipoprotein A1 gene in hyperlipidaemic and normal individuals. Clin Genet 1985;28:296-306.
41. Dallinga-Thie G, Linde-Sibenius M, Rotter J, Contor RM, Xiang-dong B, Lusis AJ, et al. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. identification of different susceptibility haplotypes. J Clin Invest 1997;99:953-61.